10x Genomics, Inc. (TXG)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 172,908 | 151,654 | 153,104 | |
| Cost of products and services revenue | 47,824 | 45,261 | 48,884 | |
| Gross profit | 125,084 | 106,393 | 104,220 | |
| Selling, general and administrative | 74,434 | 81,704 | 83,039 | |
| Research and development | 61,224 | 66,174 | 62,918 | |
| Gain on settlement | 40,700 | - | - | |
| Total operating expenses | 94,958 | 147,878 | 145,957 | |
| Income (loss) from operations | 30,126 | -41,485 | -41,737 | |
| Other income (expense), net | 2,603 | 2,078 | -56 | |
| Interest income | 4,271 | 4,971 | 4,715 | |
| Interest expense | 3 | 2 | 1 | |
| Total other income | 6,871 | 7,047 | 4,658 | |
| Income (loss) before provision for income taxes | 36,997 | -34,438 | -37,079 | |
| Provision for income taxes | 2,459 | 1,315 | 818 | |
| Net income (loss) | 34,538 | -35,753 | -37,897 | |
| Net income (loss) per share, basic (in dollars per share) | 0.28 | -0.3 | -0.32 | |
| Net income (loss) per share, diluted (in dollars per share) | 0.28 | -0.3 | -0.32 | |
| Weighted-average shares used to compute net income (loss) per share, basic (in shares) | 123,755,409 | 120,733,030 | 120,066,972 | |
| Weighted-average shares used to compute net income (loss) per share, diluted (in shares) | 124,509,720 | 120,733,030 | 120,066,972 | |